Remeglurant
Remeglurant (INN; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor.[1][2][3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.[3]
Clinical data | |
---|---|
Other names | MRZ-8456 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C17H15BrN4O |
Molar mass | 371.238 g·mol−1 |
3D model (JSmol) | |
| |
|
References
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. World Health Organization. 27 (2).
- Danysz W, et al. Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators. US Patent 7985753, 4 August 2006.
- http://adisinsight.springer.com/drugs/800045269
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.